Insider Selling: Teva Pharmaceutical Industries Ltd (NYSE:TEVA) CAO Sells $18,604.08 in Stock
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) CAO Deborah A. Griffin sold 2,376 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $7.83, for a total value of $18,604.08. Following the transaction, the chief accounting officer now owns 2,376 shares of the company’s stock, valued at approximately $18,604.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Teva Pharmaceutical Industries stock opened at $7.45 on Monday. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. Teva Pharmaceutical Industries Ltd has a one year low of $6.07 and a one year high of $24.96. The stock has a market capitalization of $8.22 billion, a PE ratio of 2.66, a price-to-earnings-growth ratio of 0.79 and a beta of 1.68. The business’s fifty day moving average is $7.22 and its 200 day moving average is $10.88.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The company had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same period last year, the firm posted $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue was down 7.7% compared to the same quarter last year. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.25 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. First Interstate Bank purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $28,000. Pacer Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $32,000. Kavar Capital Partners LLC purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $35,000. G&S Capital LLC boosted its position in Teva Pharmaceutical Industries by 99.4% in the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after purchasing an additional 2,000 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its position in Teva Pharmaceutical Industries by 384.8% in the second quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares during the last quarter. 57.85% of the stock is currently owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Understanding Options Trading
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.